Search

Now showing items 1-10 of 74

Randomised controlled trial of GP-led in-hospital management of homeless people ('Pathway')

Hewett, N; Buchman, P; Musariri, J; Sargeant, C; Johnson, P; Abeysekera, K; Grant, L; Oliver, EA; Eleftheriades, C; McCormick, B;... (2016-06)

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

Foster, GR; Afdhal, N; Roberts, SK; Braeu, N; Gane, EJ; Pianko, S; Lawitz, E; Thompson, A; Shiffman, ML; Cooper, C;... (2015-12-31)

HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact

Martin, NK; Foster, GR; Vilar, J; Ryder, S; Cramp, ME; Gordon, F; Dillon, JF; Craine, N; Busse, H; Clements, A;... (2015-04)

Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection

Agarwal, K; Fung, SK; Nguyen, TT; Cheng, W; Sicard, E; Ryder, SD; Flaherty, JF; Lawson, E; Zhao, S; Subramanian, GM;... (2015-03)

Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis

Foster, GR; Irving, WL; Cheung, MCM; Walker, AJ; Hudson, BE; Verma, S; McLauchlan, J; Mutimer, DJ; Brown, A; Gelson, WTH;... (2016-06)

Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection.

Agarwal, K; Fung, SK; Nguyen, TT; Cheng, W; Sicard, E; Ryder, SD; Flaherty, JF; Lawson, E; Zhao, S; Subramanian, GM;... (2015-03)

BACKGROUND & AIMS: Tenofovir alafenamide, a phosphonate prodrug of tenofovir with greater plasma stability than tenofovir disoproxil fumarate, provides efficient delivery of active drug to hepatocytes at reduced systemic ...

Sofosbuvir-Based All-Oral Regimens for Patients with Chronic Hepatitis C Genotype 3 Infection: Integrated Analysis of Five Clinical Studies

Foster, GR; Zeuzem, S; Gane, EJ; Stedmar, CA; Feld, JJ; Mangia, A; Agarwal, K; Swain, MG; Mir, HM; Troke, P;... (2016-10)

Assessment of Bone Mineral Density in Tenofovir-Treated Patients With Chronic Hepatitis B: Can the Fracture Risk Assessment Tool Identify Those at Greatest Risk?

Gill, US; Zissimopoulos, A; Al-Shamma, S; Burke, K; McPhail, MJW; Barr, DA; Kallis, YN; Marley, RTC; Kooner, P; Foster, GR;... (2015-02-01)

Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk?.

GILL, US; Zissimopoulos, A; Al-Shamma, S; Burke, K; McPhail, MJ; Barr, DA; Yallis, YN; Marley, RT; Kooner, P; Foster, GR;... (Oxford University Press, 2014-08-25)

Abstract BACKGROUND: Tenofovir disoproxil fumarate (TDF) is an established nucleotide analogue in the treatment of chronic hepatitis B. Bone mineral density loss has been described in TDF-treated patients with human ...

Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

Zeuzem, S; Foster, GR; Wang, S; Asatryan, A; Gane, E; Feld, JJ; Asselah, T; Bourliere, M; Ruane, PJ; Wedemeyer, H;... (2018-01-25)

1
2
3
4
. . .
8